Literature DB >> 3145517

Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection.

U Bondesson1, L H Lindström.   

Abstract

A gas chromatographic-mass spectrometric method with single ion detection has been developed for determination of clozapine and its N-demethylated metabolite norclozapine in plasma. Propylnorclozapine was used as internal standard and the mass spectrometer was adjusted to record the ion m/z 373 for the compounds analyzed. The precision of the method was found to be high, with a relative standard deviation of 6% or less for replicated samples. The limit of determination was 1.0 ng/ml for clozapine and 5.0 ng/ml norclozapine. A significant correlation was obtained between the daily oral dose of clozapine within the dose interval 100-800 mg/day and the plasma level of clozapine in 22 chronic schizophrenic patients. The plasma levels of clozapine and norclozapine were also significantly correlated. The quotient norclozapine/clozapine showed great interindividual variation and was not correlated to the daily dose of clozapine. The method is rapid and sensitive to allow evaluation of the pharmacokinetic properties of clozapine in the treatment of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145517     DOI: 10.1007/bf00172957

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Measurement of plasma levels of tricylic psychoactive drugs and their metabolites by UV reflectance photometry of thin layer chromatograms.

Authors:  U Breyer; K Villumsen
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

2.  Antipsychotic drugs, neurotransmitters, and schizophrenia.

Authors:  A Carlsson
Journal:  Am J Psychiatry       Date:  1978-02       Impact factor: 18.112

3.  Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.

Authors:  J Gerlach; P Koppelhus; E Helweg; A Monrad
Journal:  Acta Psychiatr Scand       Date:  1974       Impact factor: 6.392

4.  [Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group].

Authors:  H Gross; E Langner
Journal:  Wien Med Wochenschr       Date:  1966-10-01

Review 5.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

6.  Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison.

Authors:  B Shopsin; H Klein; M Aaronsom; M Collora
Journal:  Arch Gen Psychiatry       Date:  1979-06

7.  Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties.

Authors:  B Ekblom; J E Haggstrom
Journal:  Curr Ther Res Clin Exp       Date:  1974-09

8.  The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e) (1,4)diazepine (clozapine) in mice, dogs and human subjects.

Authors:  R Gauch; W Michaelis
Journal:  Farmaco Prat       Date:  1971-11

9.  Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years.

Authors:  U Juul Povlsen; U Noring; R Fog; J Gerlach
Journal:  Acta Psychiatr Scand       Date:  1985-02       Impact factor: 6.392

10.  Agranulocytosis during treatment with chlozapine.

Authors:  J Idänpään-Heikkilä; E Alhava; M Olkinuora; I P Palva
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  16 in total

Review 1.  Mechanisms of clozapine-induced agranulocytosis.

Authors:  S L Gerson; H Meltzer
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

Review 2.  Clozapine--pharmacokinetic investigations and biochemical effects in man.

Authors:  M Ackenheil
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 3.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

4.  Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women.

Authors:  M Fabrazzo; G Esposito; R Fusco; M Maj
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Authors:  D M Weiner; H Y Meltzer; I Veinbergs; E M Donohue; T A Spalding; T T Smith; N Mohell; S C Harvey; J Lameh; N Nash; K E Vanover; R Olsson; K Jayathilake; M Lee; A I Levey; U Hacksell; E S Burstein; R E Davis; M R Brann
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

6.  CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

Authors:  C Nordin; B Almé; U Bondesson
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 7.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

8.  Identification of a novel splice-site mutation in the CYP1A2 gene.

Authors:  Delphine Allorge; Dany Chevalier; Jean-Marc Lo-Guidice; Christelle Cauffiez; Françoise Suard; Pierre Baumann; Chin B Eap; Franck Broly
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

9.  Rapid liquid chromatography/tandem mass spectrometer (LCMS) method for clozapine and its metabolite N-desmethyl clozapine (norclozapine) in human serum.

Authors:  L V Rao; M L Snyder; G M Vallaro
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 10.  Pharmacokinetics and pharmacodynamics of clozapine.

Authors:  M W Jann; S R Grimsley; E C Gray; W H Chang
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.